Creative Planning Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Creative Planning bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,002 shares of the company’s stock, valued at approximately $362,000.

Several other hedge funds have also added to or reduced their stakes in TARS. Quest Partners LLC bought a new stake in Tarsus Pharmaceuticals in the second quarter worth $61,000. Canada Pension Plan Investment Board bought a new stake in Tarsus Pharmaceuticals in the second quarter worth $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after acquiring an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at $202,000. Finally, Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals during the first quarter valued at $223,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 0.0 %

Tarsus Pharmaceuticals stock opened at $46.79 on Friday. The stock has a market cap of $1.78 billion, a PE ratio of -10.40 and a beta of 1.00. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03. Tarsus Pharmaceuticals, Inc. has a one year low of $15.47 and a one year high of $51.59. The stock has a fifty day moving average of $35.12 and a 200 day moving average of $31.80.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The company had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. During the same quarter in the prior year, the business earned ($1.17) earnings per share. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reaffirmed an “outperform” rating and set a $63.00 price target (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $51.60.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.